Ticker: CBPO, Company: China Biologic Products, Inc., Type: 8-K, Date: 2016-10-11
Original SEC Filing: Click here

---

Webplus: CBPO/20161011/8-K/2_EX-99.1/000.htm SEC Original: v450369_ex99-1.htm
FOR RELEASE October 11, 2016 China Biologic Receives CFDA Clinical Trial Approval for Human Antithrombin III BEIJING, China – October 11, 2016 – ATIII is intended to treat hereditary and acquired ATIII deficiency in connection with surgical or obstetrical procedures, and to treat thromboembolism. No manufacturer in China currently offers plasma-derived ATIII product. China Biologic expects to commence clinical trials

---

---

Webplus: CBPO/20161011/8-K/1/000.htm SEC Original: v450369_8k.htm

---

Company Info:

Ticker: CBPO, Company: China Biologic Products, Inc., Type: 8-K, Date: 2016-10-11CIK: 0001369868, Location: F4, SIC: 2836, SIC Desc: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Business Phone & Address:
18TH FL, JIALONG INTERNATIONALBUILDING, 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
BEIJING 100125